BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

NCT00098254 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

NIH

Sponsor class

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

DRUG: BAY 43-9006 (Sorafenib)

Sponsor

National Cancer Institute (NCI)